XML 103 R52.htm IDEA: XBRL DOCUMENT
v3.23.4

The Company and Basis of Presentation - Narrative (Details) $ / shares in Units, $ in Thousands |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Jun. 26, 2023 USD ($) shares | Jun. 22, 2023 $ / shares shares | Apr. 30, 2023 employee | Jun. 30, 2023 | Sep. 30, 2023 USD ($) SEGMENT $ / shares | Dec. 31, 2022 USD ($) SEGMENT $ / shares | Dec. 31, 2021 USD ($) $ / shares
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |
Number of operating segments | SEGMENT |  |  |  |  | 1 | 1 |
Employee workforce, termination percentage |  |  | 83.00% | 83.00% |  |  |
Preferred stock, par value (in dollars per share) | $ / shares |  |  |  |  | $ 0.0001 | $ 0.0001 | $ 0.0001
Accumulated deficit | $ |  |  |  |  | $ 701,234 | $ 425,624 | $ 341,809
Cash, cash equivalents, and marketable securities | $ |  |  |  |  | $ 203,600 |  |
Number of employees retained | employee |  |  | 10 |  |  |  |
Working capital | $ |  |  |  |  |  | 47,600 |
Cash, cash equivalents, marketable securities, and restricted cash | $ |  |  |  |  |  | $ 57,300 |
Asset Acquisition |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |
Fixed exchange ratio |  | 0.54945% |  |  |  |  |
Spyre Therapeutics, Inc. |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |
Asset acquisition, stockholder payment period |  | 3 years |  |  |  |  |
Asset acquisition, cash payment, threshold period |  | 1 year |  |  |  |  |
Spyre 2023 Equity Incentive Plan | Asset Acquisition |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |
Number of outstanding and unexercised stock options to purchase (in shares) | shares |  | 2,734 |  |  |  |  |
Spyre 2023 Equity Incentive Plan | Spyre Therapeutics, Inc. |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |
Number of outstanding and unexercised stock options to purchase (in shares) | shares |  | 2,734 |  |  |  |  |
Series A Non Voting Convertible Preferred Stock |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |
Conversion basis |  | 40 |  |  |  |  |
Series A Non Voting Convertible Preferred Stock | Asset Acquisition |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |
Number of shares transferred as equity interest in asset acquisition | shares |  | 364,887 |  |  |  |  |
Preferred stock, par value (in dollars per share) | $ / shares |  | $ 0.0001 |  |  |  |  |
Conversion basis |  | 40 |  |  |  |  |
Series A Non Voting Convertible Preferred Stock | Spyre Therapeutics, Inc. |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |
Number of shares transferred as equity interest in asset acquisition | shares |  | 364,887 |  |  |  |  |
Private Placement | Series A Non Voting Convertible Preferred Stock |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |
Number of shares sold in private placement | shares | 721,452 |  |  |  |  |  |
Gross proceeds received in private placement | $ | $ 210,000 |  |  |  |  |  |
Placement agent and other offering expenses in private placement | $ | $ 12,700 |  |  |  |  |  |
Common Stock | Asset Acquisition |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |
Number of shares transferred as equity interest in asset acquisition | shares |  | 517,809 |  |  |  |  |

X
- Definition Asset Acquisition, Cash Payment, Threshold Period + References No definition available. + Details
Name: | agle_AssetAcquisitionCashPaymentThresholdPeriod
Namespace Prefix: | agle_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset acquisition consideration transferred equity interest issued and issuable, shares. + References No definition available. + Details
Name: | agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
Namespace Prefix: | agle_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Stockholder Payment Period + References No definition available. + Details
Name: | agle_AssetAcquisitionStockholderPaymentPeriod
Namespace Prefix: | agle_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash, cash equivalents, marketable securities and restricted cash. + References No definition available. + Details
Name: | agle_CashCashEquivalentsMarketableSecuritiesAndRestrictedCash
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Company and basis of presentation. + References No definition available. + Details
Name: | agle_CompanyAndBasisOfPresentationLineItems
Namespace Prefix: | agle_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fixed exchange ratio. + References No definition available. + Details
Name: | agle_FixedExchangeRatio
Namespace Prefix: | agle_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of employees retained. + References No definition available. + Details
Name: | agle_NumberOfEmployeesRetained
Namespace Prefix: | agle_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Outstanding and unexercised stock options. + References No definition available. + Details
Name: | agle_OutstandingAndUnexercisedStockOptions
Namespace Prefix: | agle_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Placement agent and other offering expenses. + References No definition available. + Details
Name: | agle_PlacementAgentAndOtherOfferingExpenses
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Working capital. + References No definition available. + Details
Name: | agle_WorkingCapital
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CashCashEquivalentsAndShortTermInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of warrants or rights outstanding. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18 + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of common shares issuable upon conversion for each share of preferred stock to be converted. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockConvertibleConversionRatio
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_PreferredStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfPrivatePlacement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). + References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of accumulated undistributed earnings (deficit). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=agle_Spyre2023EquityIncentivePlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |